← Back
Data updated: Mar 10, 2026
AVYXA HOLDINGS
OncologyGastroenterology
AVYXA HOLDINGS is a specialty pharmaceutical company focused on Oncology, Gastroenterology. Key products include FRINDOVYX.
2016
Since
11
Drugs
-
Trials
35
Approved (2yr)
Key Drugs
FRINDOVYX
cyclophosphamide
DNA 13 indications · 2023
DOCIVYX
docetaxel
Microtubules 5 indications · 2022
VYKOURA
leucovorin calcium
Dihydrofolate reductase 5 indications · 2026
AVGEMSI
gemcitabine hydrochloride
Ribonucleotide reductase 4 indications · 2025
FAVLYXA
fluorouracil
3 indications · 2026
Recent Activity
FAVLYXA 2026-02-20
Type 5 - New Formulation or New Manufacturer
AVOPEF 2026-02-13
Type 3 - New Dosage Form
VYKOURA 2026-02-03
Type 5 - New Formulation or New Manufacturer
FULVESTRANT 2025-11-21
Labeling
AXTLE 2025-10-03
Efficacy
FULVESTRANT 2025-09-17
Labeling
KYXATA 2025-08-08
Type 5 - New Formulation or New Manufacturer
FRINDOVYX 2025-08-01
Labeling
AVGEMSI 2025-06-27
Type 5 - New Formulation or New Manufacturer
AVGEMSI 2025-06-27
Type 5 - New Formulation or New Manufacturer
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 90%
9 drugs
Gastroenterology 10%
1 drugs
Pipeline Strength Pro
Loading...